Selecting Drug Delivery Systems For Higher Doses, Higher Viscosities, And Lower Risk
By: Nicolas Bralet and Megan Lan, MBA, MA
![iStock-1319077865-lab-team-computer-research iStock-1319077865-lab-team-computer-research](https://vertassets.blob.core.windows.net/image/292b9849/292b9849-cf6c-4701-a02c-6de30ca98e7e/375_250-istock_1319077865_lab_team_computer_research.jpg)
The development of new parenteral biologics with high-volume, high-viscosity formulations (> 1 mL, >15 cP) is triggering the need for devices that can deliver these therapies with the ease, safety, and low injection time required for self-injection.1-3 As these formulations come to market, pharmaceutical and biotech companies must make critical device choices from an array of largely unproven options.2 The following article discusses how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.